Alpha Tau Medical Ltd DRTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $12.98
- Day Range
- $12.01–13.40
- 52-Week Range
- $2.87–14.11
- Bid/Ask
- $12.80 / $13.10
- Shares Outstanding
- 90.33M
- Market Cap
- $1.15B
- Volume/Avg
- 640,601 / 859,910
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 121
- Website
- https://www.alphatau.com
Valuation
|
Metric
|
DRTS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DRTS
|
|---|---|
Quick Ratio | 7.42 |
Current Ratio | 7.79 |
Interest Coverage | −7.29 |
Quick Ratio
DRTS
Profitability
|
Metric
|
DRTS
|
|---|---|
Return on Assets (Normalized) | −55.65% |
Return on Equity (Normalized) | −77.49% |
Return on Invested Capital (Normalized) | −59.41% |
Return on Assets
DRTS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%b#?@J | LOCK|CGhMn | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%J^ntb | LOCK|X^Mw | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<^^#>S | LOCK|x$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&<r#ZF | LOCK|!@gP | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GvCN%CK | LOCK|pZS | $36B | |||
| Moderna Inc
MRNA
| LOCK|@>><mD | LOCK|L%& | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|M!>!!XJ& | LOCK|r!!B | $25B | |||
| Incyte Corp
INCY
| LOCK|^sDSpQF | LOCK|s#% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$yFK#DZ | LOCK|WL# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|C!&@#d^ | LOCK|>! | $17B |
United States